These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31013496)

  • 1. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
    de Tommaso M; Brighina F; Delussi M
    Eur Neurol; 2019; 81(1-2):37-46. PubMed ID: 31013496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
    Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
    Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Botulinum Toxin on Migraine Attack Features in Chronic Migraine: A Six-Month Open-Label Observation Study through Electronic Diary Smartphone Application.
    Santoro A; Delussi M; Leone M; Miscio AM; De Rocco L; Leo G; De Tommaso M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31731628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
    Tassorelli C; Aguggia M; De Tommaso M; Geppetti P; Grazzi L; Pini LA; Sarchielli P; Tedeschi G; Martelletti P; Cortelli P
    J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
    Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous allodynia and thermal thresholds in chronic migraine: The effect of onabotulinumtoxinA.
    Ozarslan M; Matur Z; Tuzun E; Oge AE
    Clin Neurol Neurosurg; 2022 Sep; 220():107357. PubMed ID: 35792471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pregabalin on central sensitization in patients with migraine.
    Zhang N; Chen CF; Yu FY
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):277-83. PubMed ID: 25669613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine.
    Argyriou AA; Dermitzakis EV; Rikos D; Xiromerisiou G; Soldatos P; Litsardopoulos P; Vikelis M
    Toxins (Basel); 2024 Feb; 16(2):. PubMed ID: 38393184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.
    Montisano DA; Giossi R; Canella M; Altamura C; Marcosano M; Vernieri F; Raggi A; Grazzi L
    Toxins (Basel); 2024 Apr; 16(4):. PubMed ID: 38668603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
    Dodick DW
    Headache; 2003; 43 Suppl 1():S25-33. PubMed ID: 12887391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A in refractory chronic migraine: an open-label trial.
    Menezes C; Rodrigues B; Magalhães E; Melo A
    Arq Neuropsiquiatr; 2007 Sep; 65(3A):596-8. PubMed ID: 17876397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
    Binder WJ; Brin MF; Blitzer A; Schoenrock LD; Pogoda JM
    Otolaryngol Head Neck Surg; 2000 Dec; 123(6):669-76. PubMed ID: 11112955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
    Freitag FG
    CNS Drugs; 2003; 17(6):373-81. PubMed ID: 12696998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
    Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
    Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
    Dowson AJ; Kilminster SG; Salt R
    Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.